Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.3193730350310
   PubMed Web of Science ®Google Scholar
• Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117(2):294–299. doi:10.1002/(ISSN)1097-021515900604
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a national cancer database survey. J Thorac Oncol. 2010;5(1):29–33. doi:10.1097/JTO.0b013e3181c5920c19952801
   PubMed Web of Science ®Google Scholar
• Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382(9893):709–719. doi:10.1016/S0140-6736(13)61502-023972814
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377(9):849–861. doi:10.1056/NEJMra170341328854088
   PubMed Web of Science ®Google Scholar
• Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943–953. doi:10.2147/CMAR.S18731730718965
   PubMed Web of Science ®Google Scholar
• Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist. 1999;4(5):408–416.10551557
   PubMedGoogle Scholar
• Belani CP. Paclitaxel and docetaxel combinations in non-small cell lung cancer. Chest. 2000;117(4Suppl 1):144S–141S. doi:10.1378/chest.117.4_suppl_1.144s10777470
   PubMedGoogle Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550. doi:10.1056/NEJMoa06188417167137
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617–4625. doi:10.1200/JCO.2008.17.7162.18678835
   PubMed Web of Science ®Google Scholar
• Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene. 2003;22(47):7280–7295. doi:10.1038/sj.onc.120693414576838
   PubMed Web of Science ®Google Scholar
• Wang S, Zhu L, Zuo W, et al. MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. Oncotarget. 2016;7(25):37693–37713. doi:10.18632/oncotarget.926427177222
   PubMedGoogle Scholar
• Wang S, Huang X, Lee CK, Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene. 2010;29(29):4225–4236. doi:10.1038/onc.2010.18020498641
   PubMed Web of Science ®Google Scholar
• Wang S, Huang J, Lyu H, et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis. 2013;4:e556. doi:10.1038/cddis.2013.7923519125
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.050658010216199517
   PubMed Web of Science ®Google Scholar
• Garofalo M, Croce CM. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat. 2013;16(3–5):47–59. doi:10.1016/j.drup.2013.05.00123757365
   PubMed Web of Science ®Google Scholar
• Xie S, Ogden A, Aneja R, Zhou J. Microtubule-binding proteins as promising biomarkers of paclitaxel sensitivity in cancer chemotherapy. Med Res Rev. 2016;36(2):300–312. doi:10.1002/med.2137826332739
   PubMed Web of Science ®Google Scholar
• Shi X, Sun X. Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy. Cancer Chemother Pharmacol. 2017;80(5):909–917. doi:10.1007/s00280-017-3398-228741098
   PubMed Web of Science ®Google Scholar
• Amos LA, Löwe J. How Taxol stabilises microtubule structure. Chem Biol. 1999;6(3):65–69. doi:10.1016/S1074-5521(99)89002-4
   Google Scholar
• Gonçalves A, Braguer D, Kamath K, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA. 2001;98(20):11737–11742. doi:10.1073/pnas.19138859811562465
   PubMed Web of Science ®Google Scholar
• Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997;100(5):1282–1293. doi:10.1172/JCI1196429276747
   PubMed Web of Science ®Google Scholar
• Atjanasuppat K, Lirdprapamongkol K, Jantaree P, Svasti J. Non-adherent culture induces paclitaxel resistance in H460 lung cancer cells via ERK-mediated up-regulation of βIVa-tubulin. Biochem Biophys Res Commun. 2015;466(3):493–498. doi:10.1016/j.bbrc.2015.09.05726375501
   PubMed Web of Science ®Google Scholar
• Yu D, Jing T, Liu B, et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell. 1998;2(5):581–591.9844631
   PubMed Web of Science ®Google Scholar
• Chen J, Ren Q, Cai Y, et al. Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1. Biochem Biophys Res Commun. 2018;501(1):212–219. doi:10.1016/j.bbrc.2018.04.21829715459
   PubMed Web of Science ®Google Scholar
• Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992;3(10):1141–1154. doi:10.1091/mbc.3.10.11411421571
   PubMed Web of Science ®Google Scholar
• Kar S, Fan J, Smith MJ, Goedert M, Amos LA. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J. 2003;22(1):70–77. doi:10.1093/emboj/cdg00112505985
   PubMed Web of Science ®Google Scholar
• Mimori K, Sadanaga N, Yoshikawa Y, et al. Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br J Cancer. 2006;94(12):1894–1897. doi:10.1038/sj.bjc.660318216721363
   PubMed Web of Science ®Google Scholar
• Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B, Szczylik C. The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol. 2001;68(3):553–557. doi:10.1007/s00280-011-1696-7
   Google Scholar
• Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle. 2005;4(9):1149–1152. doi:10.4161/cc.4.9.203816103753
   PubMed Web of Science ®Google Scholar
• Wu H, Huang M, Lu M, et al. Regulation of microtubule- associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol. 2013;71(5):1159–1171. doi:10.1007/s00280-013-2108-y23423488
   PubMed Web of Science ®Google Scholar
• Ye J, Zhang Z, Sun L, Fang Y, Xu X, Zhou G. miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). Mol Biosyst. 2016;12(11):3417–3424. doi:10.1039/c6mb00576d27714074
   PubMedGoogle Scholar